$SLNO
SOLENO THERAPEUTICS INC

2021 Q4 Form 10-K Financial Statement

#000156459022013023 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.596M $10.81M $2.250M
YoY Change 15.38% 23.36% 39.75%
% of Gross Profit
Research & Development $3.734M $21.45M $5.570M
YoY Change -32.96% -7.49% 5.69%
% of Gross Profit
Depreciation & Amortization $492.0K $19.00K $480.0K
YoY Change 2.5% 72.73% -2.04%
% of Gross Profit
Operating Expenses $3.001M $31.53M $7.820M
YoY Change -61.62% -13.12% 13.66%
Operating Profit -$31.53M
YoY Change -13.12%
Interest Expense $34.00K $110.0K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $139.0K $508.0K $5.110M
YoY Change -97.28% -95.64% -164.93%
Pretax Income -$2.828M -$30.91M -$2.850M
YoY Change -0.77% 25.45% -80.52%
Income Tax
% Of Pretax Income
Net Earnings -$2.828M -$30.90M -$2.850M
YoY Change -0.77% 25.41% -80.52%
Net Earnings / Revenue
Basic Earnings Per Share -$5.81
Diluted Earnings Per Share -$35.42K -$387.5K -$35.75K
COMMON SHARES
Basic Shares Outstanding 5.318M
Diluted Shares Outstanding 5.318M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.30M $21.30M $49.22M
YoY Change -56.72% -56.72% 137.43%
Cash & Equivalents $21.30M $21.30M $49.22M
Short-Term Investments
Other Short-Term Assets $1.118M $1.118M $1.020M
YoY Change 9.61% 9.61% 148.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.42M $22.42M $50.24M
YoY Change -55.37% -55.37% 137.62%
LONG-TERM ASSETS
Property, Plant & Equipment $33.00K $454.0K $19.00K
YoY Change 73.68% 183.75% -13.64%
Goodwill
YoY Change
Intangibles $12.64M $14.58M
YoY Change -13.33% -11.76%
Long-Term Investments
YoY Change
Other Assets $40.00K $40.00K $15.00K
YoY Change 166.67% -74.58%
Total Long-Term Assets $13.13M $13.13M $14.74M
YoY Change -10.91% -10.92% -13.44%
TOTAL ASSETS
Total Short-Term Assets $22.42M $22.42M $50.24M
Total Long-Term Assets $13.13M $13.13M $14.74M
Total Assets $35.55M $35.55M $64.98M
YoY Change -45.29% -45.29% 70.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.254M $3.254M $3.489M
YoY Change -6.74% -6.76% 74.89%
Accrued Expenses $4.430M $4.430M $4.930M
YoY Change -10.14% -10.14% 90.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $8.007M $8.007M $8.618M
YoY Change -7.09% -7.11% 73.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.753M $9.753M $10.82M
YoY Change -9.86% -9.86% 7260.54%
Total Long-Term Liabilities $9.753M $9.753M $10.82M
YoY Change -9.86% -9.86% 7260.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.007M $8.007M $8.618M
Total Long-Term Liabilities $9.753M $9.753M $10.82M
Total Liabilities $17.76M $17.76M $19.44M
YoY Change -8.62% -8.64% -16.32%
SHAREHOLDERS EQUITY
Retained Earnings -$213.4M -$182.4M
YoY Change 16.94% 15.61%
Common Stock $231.1M $228.0M
YoY Change 1.38% 31.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.79M $17.79M $45.55M
YoY Change
Total Liabilities & Shareholders Equity $35.55M $35.55M $64.98M
YoY Change -45.29% -45.29% 70.23%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.828M -$30.90M -$2.850M
YoY Change -0.77% 25.41% -80.52%
Depreciation, Depletion And Amortization $492.0K $19.00K $480.0K
YoY Change 2.5% 72.73% -2.04%
Cash From Operating Activities -$6.863M -$27.80M -$6.860M
YoY Change 0.04% 10.21% 35.04%
INVESTING ACTIVITIES
Capital Expenditures -$13.00K -$22.00K -$10.00K
YoY Change 30.0% -414.29%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$13.00K -$22.00K -$10.00K
YoY Change 30.0% 214.29% -110.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.000K -128.0K -40.00K
YoY Change -87.5% -100.24% -100.28%
NET CHANGE
Cash From Operating Activities -6.863M -27.80M -6.860M
Cash From Investing Activities -13.00K -22.00K -10.00K
Cash From Financing Activities -5.000K -128.0K -40.00K
Net Change In Cash -6.881M -27.80M -6.910M
YoY Change -0.42% -197.57% -172.74%
FREE CASH FLOW
Cash From Operating Activities -$6.863M -$27.80M -$6.860M
Capital Expenditures -$13.00K -$22.00K -$10.00K
Free Cash Flow -$6.850M -$27.78M -$6.850M
YoY Change 0.0% 10.09% 34.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
SLNO
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 slno Issuance Of Restricted Stock Units Value And Option Exercises Under Equity Incentive Plan
IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan
17000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3778000
CY2021 us-gaap Profit Loss
ProfitLoss
-30910000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11637000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
17000
CY2020 us-gaap Profit Loss
ProfitLoss
-24639000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53722000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1963000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1954000
CY2021 slno Noncash Lease Expense
NoncashLeaseExpense
288000
CY2020 slno Noncash Lease Expense
NoncashLeaseExpense
283000
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2020Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3276000
CY2021 dei Auditor Name
AuditorName
Marcum LLP
CY2021 dei Auditor Location
AuditorLocation
San Francisco, CA
CY2021 dei Auditor Firm
AuditorFirmId
688
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21304000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49224000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1118000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1019000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
421000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
124000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
15000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12637000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14581000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40000
CY2021Q4 us-gaap Assets
Assets
35553000
CY2020Q4 us-gaap Assets
Assets
64982000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3254000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3489000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
728000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1005000
CY2021Q4 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3420000
CY2020Q4 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3789000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
282000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
139000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
323000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
196000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8007000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8618000
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
9547000
CY2020Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
10278000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
175000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
80000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227912000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182445000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64982000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1500000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-508000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11637000
CY2021 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
-731000
CY2020 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
4340000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
139000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
549000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-235000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1494000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-277000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
722000
CY2021 slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
-369000
CY2020 slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
1790000
CY2021 slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-263000
CY2020 slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-305000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
135000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-177000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
120000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28491000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
581000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-30900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213400000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21300000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27800000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contactor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition. </p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at one U.S. commercial bank. Cash and cash equivalents deposited with this commercial bank exceeded the Federal Deposit Insurance Corporation insurable limit at December 31, 2021 and 2020. The Company expects the maintenance of balances in excess of insurable limits will continue. </p>
CY2021Q4 slno Concentration Risk Credit Risk Numberof Banks
ConcentrationRiskCreditRiskNumberofBanks
1
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Depreciation
Depreciation
19000
CY2020 us-gaap Depreciation
Depreciation
11000
CY2021 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
CY2021 slno Percentage Of Probability Of Achieving Milestone
PercentageOfProbabilityOfAchievingMilestone
0.72
CY2020 slno Percentage Of Probability Of Achieving Milestone
PercentageOfProbabilityOfAchievingMilestone
0.67
CY2021Q4 slno Commercial Milestones In Applicable Revenue Year Three
CommercialMilestonesInApplicableRevenueYearThree
100000000.0
CY2021Q4 slno Commercial Milestones In Applicable Revenue Year Four
CommercialMilestonesInApplicableRevenueYearFour
200000000.0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
101000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
68000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19000
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1900000
CY2020 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1900000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
8000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
200000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
6000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
14000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
24000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
15000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000
CY2020 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2021 slno Finance Lease Cost
FinanceLeaseCost
4000
CY2020 slno Finance Lease Cost
FinanceLeaseCost
11000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
277000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
336000
CY2020 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
17000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
315000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
179000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
494000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
37000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
457000
CY2020Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.10
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2020 slno Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
-2444000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3300000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1500000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3276000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1500000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.04
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.78
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.70
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.76
CY2021 slno Income Tax Reconciliation Change In Fair Value Of Contingent Consideration
IncomeTaxReconciliationChangeInFairValueOfContingentConsideration
-153000
CY2020 slno Income Tax Reconciliation Change In Fair Value Of Contingent Consideration
IncomeTaxReconciliationChangeInFairValueOfContingentConsideration
911000
CY2021 slno Income Tax Reconciliation Change In Net Operating Loss
IncomeTaxReconciliationChangeInNetOperatingLoss
-712000
CY2020 slno Income Tax Reconciliation Change In Net Operating Loss
IncomeTaxReconciliationChangeInNetOperatingLoss
-846000
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-20000
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
104000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
48542000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41999000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3312000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30453000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22197000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-457000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2442000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30910000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24639000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6501000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5174000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2342000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2293000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
12000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
51000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8711000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8231000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
364000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
303000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
52000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
71000
CY2021 slno Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
-107000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2803000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
573000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
236000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
59000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
63000
CY2021Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1115000
CY2020Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1115000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1133000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
337000
CY2021Q4 slno Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
133000
CY2020Q4 slno Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
41000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
102000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
129000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54969000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46723000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3536000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
4080000
CY2021Q4 slno Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
118000
CY2020Q4 slno Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
39000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
42604000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4119000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
51315000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51315000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3654000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42604000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8700000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1323000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1111000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
4000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
234000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
216000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1557000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1323000
CY2021Q4 slno Unrecognized Assets And Liabilities Related To Uncertain Tax Positions
UnrecognizedAssetsAndLiabilitiesRelatedToUncertainTaxPositions
1600000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021Q4 slno Unrecognized Tax Benefits Offset By Valuation Allowance
UnrecognizedTaxBenefitsOffsetByValuationAllowance
1600000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7193486
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4050926
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0

Files In Submission

Name View Source Status
0001564590-22-013023-index-headers.html Edgar Link pending
0001564590-22-013023-index.html Edgar Link pending
0001564590-22-013023.txt Edgar Link pending
0001564590-22-013023-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-10k_20211231.htm Edgar Link pending
slno-10k_20211231_htm.xml Edgar Link completed
slno-20211231.xsd Edgar Link pending
slno-20211231_cal.xml Edgar Link unprocessable
slno-20211231_def.xml Edgar Link unprocessable
slno-20211231_lab.xml Edgar Link unprocessable
slno-20211231_pre.xml Edgar Link unprocessable
slno-ex211_7.htm Edgar Link pending
slno-ex231_6.htm Edgar Link pending
slno-ex311_8.htm Edgar Link pending
slno-ex312_11.htm Edgar Link pending
slno-ex321_9.htm Edgar Link pending
slno-ex322_10.htm Edgar Link pending